Mural Oncology plc, a clinical-stage immuno-oncology company, has published a definitive proxy statement for the Acquisition by XOMA Royalty Corporation. The Proxy Statement includes details about the Acquisition, the meetings for Mural shareholders, and actions to be taken. The Scheme Meeting will be held on October 24, 2025, in Dublin, Ireland. Mural announced the discontinuation of clinical development of nemvaleukin for cancer treatment. The Acquisition is being made solely by means of a Proxy Statement distributed to Mural’s shareholders. Participants in the solicitation include Mural’s directors and executive officers.

Read more at GlobeNewswire: Mural Oncology Announces Commencement of Mailing of